Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXLINEAR, INCMXL · Entity 3882 | Director | May 20, 2026 | May 22, 2026 |
| MEDICINOVA INCMNOV · Entity 7011 | Director | June 23, 2026 | June 25, 2026 |
| Sonendo, Inc.SONX · Entity 9738 | Director | September 17, 2024 | September 19, 2024 |
| VivoSim Labs, INC.ONVO · Entity 8386 | Director | September 05, 2019 | September 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXLINEAR, INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,963 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,963 · Balance 1,963 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2027 or the date immediately preceding the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2027 or the date immediately preceding the next annual meeting of stockholders.
MEDICINOVA INC
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-06-22 | Direct | 44,500 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 44,500 · Balance 44,500 F1: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.
Sonendo, Inc.
Report date September 17, 2024 · Filed September 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,798 |
Reported balance
After 2024-09-17 transaction · row 1
1 source rowRow 1 · 2024-09-17 · Grant · Acquired 200,000 · Balance 262,798 F1: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
VivoSim Labs, INC.
Report date September 05, 2019 · Filed September 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.27 · Expires 2029-09-05 | Direct | 52,000 |
Reported balance
After 2019-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-05 · Grant · Acquired 52,000 · Balance 52,000 F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 116,990 · Balance 0 F1: Includes 9,423 shares acquired 7/29/16 pursuant to the Issuer's Employee Stock Purchase Plan. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-09-07 · Other · Disposed 50,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-07 · Disposition to issuer · Disposed 59,139 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2024-01-31 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-07 · Disposition to issuer · Disposed 36,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-07 · Disposition to issuer · Disposed 147,861 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-07 · Disposition to issuer · Disposed 1,713 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-09-07 · Disposition to issuer · Disposed 9,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-09-07 · Disposition to issuer · Disposed 7,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-09-07 · Disposition to issuer · Disposed 54,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2016-09-07 · Disposition to issuer · Disposed 155,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 9,423 shares acquired 7/29/16 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock.
F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 20:35 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 44,500 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001683168-26-005109 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2036-06-22 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company. Read SEC document |
| May 20, 2026 Filed May 22, 2026 21:35 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 1,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001335581-26-000004 · wk-form4_1779485722.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,963 Underlying: Common Stock · 1,963 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2027 or the date immediately preceding the next annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2027 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| May 04, 2026 Filed May 5, 2026 20:11 UTC | MAXLINEAR, INC MXL · Entity 3882 | SaleCommon Stock | 6,000 | $76.96 | $461,746.80 |
DisclosureSEC source: 0001335581-26-000002 · wk-form4_1778011905.xml · nonDerivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,316 F1 · price: Represents the weighted average share price of an aggregate total of 6,000 shares sold in the price range of $76.95 to $77.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:11 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionRestricted Stock Units · Derivative | 15,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001335581-26-000002 · wk-form4_1778011905.xml · derivative · entry 3 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to the award vested on May 1, 2026. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to the award vested on May 1, 2026. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:11 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionCommon Stock | 15,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001335581-26-000002 · wk-form4_1778011905.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:10 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001683168-25-004648 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026, subject to continued service with the Company. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:27 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 18,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-25-000065 · wk-form4_1747945620.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,227 Underlying: Common Stock · 18,227 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2026 or the date immediately preceding the next annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2026 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| May 20, 2025 Filed Oct 10, 2025 22:44 UTC Amendment | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 15,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001335581-25-000005 · wk-form4a_1760136268.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,741 Underlying: Common Stock · 15,741 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · shares: This amendment is being filed to correct the number of RSUs reported in the Form 4 filed May 22, 2025. F3 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2026 or the date immediately preceding the next annual meeting of stockholders. F3 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2026 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:48 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionRestricted Stock Units · Derivative | 12,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-25-000041 · wk-form4_1746488906.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to the award vested on May 1, 2025. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to the award vested on May 1, 2025. Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:48 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionCommon Stock | 12,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-25-000041 · wk-form4_1746488906.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:49 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 24,500 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001683168-25-001042 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2035-02-11 F1 · derivative.exercise_date: The option vests in four equal installments on May 12, 2025, August 12, 2025, November 12, 2025 and February 12, 2026, subject to continued service with the Company. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:39 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-108201 · ownership.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,798 F1 · kind: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 23:40 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001683168-24-004154 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025, subject to continued service with the Company. Read SEC document |
| May 23, 2024 Filed May 24, 2024 22:42 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 12,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-24-000086 · wk-form4_1716590529.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,141 Underlying: Common Stock · 12,141 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2025 or the date immediately preceding the next annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2025 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 01:03 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantStock Option (Right to Buy) · Derivative | 32,520 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001562180-23-005391 · primarydocument.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,520 Underlying: Common Stock · 32,520 shares Expires 2033-06-15 F2 · derivative.exercise_date: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 01:03 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 25,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005391 · primarydocument.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,798 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:03 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001683168-23-004188 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, subject to continued service with the Company. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:05 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 9,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-23-000116 · wf-form4_168383551997990.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,170 Underlying: Common Stock · 9,170 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2024 or the date immediately preceding the next annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2024 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 12:46 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantStock Options (Right to buy) · Derivative | 49,586 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001562180-22-005425 · primarydocument.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,586 Underlying: Common Stock · 49,586 shares Expires 2032-06-28 F2 · derivative.exercise_date: The Options vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date and (ii) the date of the 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 12:46 UTC | Sonendo, Inc. SONX · Entity 9738 | GrantCommon Stock | 34,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005425 · primarydocument.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,482 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 21:22 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001683168-22-004428 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023, subject to continued service with the Company. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:25 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 5,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-22-000134 · wf-form4_165402871981929.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,633 Underlying: Common Stock · 5,633 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2023 or the date immediately preceding the 2023 annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2023 or the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:28 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionRestricted Stock Units · Derivative | 2,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-21-000274 · wf-form4_163848050495254.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:28 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionCommon Stock | 2,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-21-000274 · wf-form4_163848050495254.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 21:23 UTC | Sonendo, Inc. SONX · Entity 9738 | PurchaseCommon Stock | 2,800 | $12.00 | $33,600.00 |
DisclosureSEC source: 0000899243-21-042414 · doc4.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 19:47 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001683168-21-002631 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2021, December 31, 2021, March 31, 2022 and June 30, 2022, subject to continued service with the Company. Read SEC document |
| May 12, 2021 Filed May 13, 2021 22:35 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 5,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-21-000121 · wf-form4_162094531137848.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,944 Underlying: Common Stock · 5,944 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2022 or the date immediately preceding the 2022 annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2022 or the date immediately preceding the 2022 annual meeting of stockholders. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:09 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionRestricted Stock Units · Derivative | 2,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-20-000253 · wf-form4_160694337077175.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,696 Underlying: Common Stock · 2,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the 8,088 RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the 8,088 RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:09 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionCommon Stock | 2,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-20-000253 · wf-form4_160694337077175.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:30 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001683168-20-003513 · ownership.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-10-19 F1 · derivative.exercise_date: The option vests in three equal installments on December 31, 2020, March 31, 2021 and June 30, 2021, subject to continued service with the Company. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:07 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 1,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-20-000206 · wf-form4_159985486324329.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 Underlying: Common Stock · 1,165 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:29 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 7,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-20-000131 · wf-form4_159182098128633.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,890 Underlying: Common Stock · 7,890 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:40 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionRestricted Stock Units · Derivative | 2,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-19-000200 · wf-form4_157541283723755.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,392 Underlying: Common Stock · 2,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:40 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionCommon Stock | 2,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-19-000200 · wf-form4_157541283723755.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 22:54 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001209191-19-048953 · doc4.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2029-09-05 F1 · derivative.exercise_date: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:16 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 30,500 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001209191-19-041714 · doc4.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2029-07-08 F2 · derivative.exercise_date: The option shares vest and become exercisable in full immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:16 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001209191-19-041714 · doc4.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2029-07-08 F1 · derivative.exercise_date: The option shares vest and become exercisable over 12 equal quarterly installments measured from February 19, 2019. Read SEC document |
| May 09, 2019 Filed May 10, 2019 23:37 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 6,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-19-000075 · wf-form4_155753145967733.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,545 Underlying: Common Stock · 6,545 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2020 or the date immediately preceding the 2020 annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2020 or the date immediately preceding the 2020 annual meeting of stockholders. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:57 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionRestricted Stock Units · Derivative | 3,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-19-000063 · wf-form4_155683426125863.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award vested on May 1, 2019. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award vested on May 1, 2019. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:57 UTC | MAXLINEAR, INC MXL · Entity 3882 | Exercise / conversionCommon Stock | 3,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001288469-19-000063 · wf-form4_155683426125863.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:10 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 8,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060826 · doc4.xml · derivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,088 Underlying: Common Stock · 8,088 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. F3 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through each such date, one-third (1/3rd) of the RSUs subject to the award shall vest on each anniversary of December 1, 2018, such that the award will be fully vested on December 1, 2021. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:10 UTC | MAXLINEAR, INC MXL · Entity 3882 | GrantRestricted Stock Units · Derivative | 3,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060826 · doc4.xml · derivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,346 Underlying: Common Stock · 3,346 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2019 or the date immediately preceding the 2019 annual meeting of stockholders. F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2019 or the date immediately preceding the 2019 annual meeting of stockholders. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerRestricted Stock Unit · Derivative | 155,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 10 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · price: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.expiration_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerRestricted Stock Unit · Derivative | 54,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 9 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · price: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.expiration_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerRestricted Stock Unit · Derivative | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 8 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · price: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.expiration_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerRestricted Stock Unit · Derivative | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 7 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · price: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.expiration_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerRestricted Stock Unit · Derivative | 1,713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 6 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,713 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · price: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.expiration_date: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 147,861 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 5 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 147,861 shares Expires 2026-01-25 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerIncentive Stock Option (right to buy) · Derivative | 36,000 | Not disclosed Strike: $2.27 | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 4 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2024-01-31 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerIncentive Stock Option (right to buy) · Derivative | 59,139 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · derivative · entry 3 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,139 shares Expires 2026-01-25 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.